Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Evidence-based medicine: promise and pitfalls.

Goodin DS, Reder AT.

Mult Scler. 2012 Jul;18(7):947-8. doi: 10.1177/1352458512451660. No abstract available.

PMID:
22740607
2.

The AAN response to evidence-based medicine: promise and pitfalls.

Gronseth GS, Ashman E.

Mult Scler. 2012 Jul;18(7):949-50. doi: 10.1177/1352458512448449. No abstract available.

PMID:
22740608
3.

[Drug therapy of multiple sclerosis].

Kinnunen E.

Duodecim. 1999;115(4):403-7. Review. Finnish. No abstract available.

PMID:
11830889
4.

[Better life expectations of SM patients: 21 years follow up of patients treated with interferon beta-1b].

Komoly S.

Ideggyogy Sz. 2013 Mar 30;66(3-4):143-4. Hungarian. No abstract available.

PMID:
23750430
5.

Efficacy and safety of prolonged immunomodulatory treatment with interferon beta.

Demina TL, Khachanova NV, Davydovskaya MV, Popova NF, Gusev EI.

Neurosci Behav Physiol. 2009 Jun;39(5):497-9. doi: 10.1007/s11055-009-9151-5. Review. No abstract available.

PMID:
19430980
6.

Pearls and pitfalls of interferon beta treatment for multiple sclerosis.

Corona T, León C, Ruiz JL.

Neurologia. 1999 Nov;14(9):467-8. No abstract available.

PMID:
10613023
7.

Treatment of multiple sclerosis with interferon beta-1 b.

Abdul-Ahad A, Shah S, Galazka A.

Neurology. 1997 Aug;49(2):641-2. No abstract available.

PMID:
9270626
8.

Needed in MS: evidence, not EVIDENCE.

Kieburtz K, McDermott M.

Neurology. 2002 Nov 26;59(10):1482-3. No abstract available.

PMID:
12451186
9.

Seeing injectable ms therapies differently: they are more similar than different.

Johnson KP, Fox RJ, Arnold DL.

Neurology. 2010 Feb 23;74(8):702. doi: 10.1212/WNL.0b013e3181c77773. No abstract available.

PMID:
20177129
10.

[The BCTRIMS expanded consensus on treatment of multiple sclerosis: II. The evidences for the use of glucocorticoids and immunomodulatory treatments].

Moreira MA, Lana-Peixoto MA, Callegaro D, Haussen SR, Gama PD, Gabbai AA, Rocha FC, Lino AM; Participantes da Reunião do Consenso Expandido sobre Tratamento da Esclerose Múltipla do Comitê Brasileiro de Tratamento e Pesquisa em Esclerose Múltipla (BCTRIMS)..

Arq Neuropsiquiatr. 2002 Sep;60(3-B):875-80. Review. Portuguese.

11.

10 years of interferon beta-1b (Beta feron therapy.

Kappos L, Hartung HP.

J Neurol. 2005 Sep;252 Suppl 3:iii1-iii2. Review. No abstract available.

PMID:
16170493
12.

Multiple sclerosis and interferon beta-1b, past, present and future.

Horowski R.

Clin Neurol Neurosurg. 2002 Jul;104(3):259-64. Review. No abstract available.

PMID:
12127665
13.

[Betaferon and therapy of multiple sclerosis--present and future].

Hohlfeld R.

Med Klin (Munich). 2001 Sep 15;96 Suppl 1:1. German. No abstract available.

PMID:
11603109
14.

Rebif offers another option for treating multiple sclerosis.

Ryan M.

J Am Pharm Assoc (Wash). 2002 Nov-Dec;42(6):889-91. Review. No abstract available.

PMID:
12482017
15.

["The largest snapshot of multiple sclerosis". Interferons compared].

[No authors listed]

MMW Fortschr Med. 2003 Jun 12;145(24):55. German. No abstract available.

PMID:
12866307
16.

[Interferon beta-1b now also for the secondary progressive form of multiple sclerosis?].

de Haan RJ, Vermeulen M.

Ned Tijdschr Geneeskd. 1999 Apr 3;143(14):709-11. Dutch.

PMID:
10347623
17.

The use of interferon beta at the time of initial diagnosis of multiple sclerosis.

Pender MP.

J Clin Neurosci. 2001 Jul;8(4):381-2. Review. No abstract available.

PMID:
11437589
18.

Interferon beta for treatment of multiple sclerosis.

Wilson BA.

Medsurg Nurs. 1995 Apr;4(2):151-3. No abstract available.

PMID:
7711824
19.

Should all patients with an initial diagnosis of multiple sclerosis be treated with beta interferon?

Hodgkinson SJ.

J Clin Neurosci. 2001 Jul;8(4):378-9. Review. No abstract available.

PMID:
11437587
20.

Betaseron for multiple sclerosis. Implications for therapeutics.

Rudick RA.

Arch Neurol. 1994 Feb;51(2):125-8. No abstract available.

PMID:
8304836

Supplemental Content

Support Center